Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
In the presence of oxygen, nitric oxide is rapidly oxidised to derivatives which are toxic to the
bronchial epithelium and alveolo-capillary membrane. Nitrogen dioxide (NO2) is the main substance
formed, and may cause airway inflammation and damage. There are also animal data suggesting an
increased susceptibility to airway infections upon exposure to low levels of NO2. During treatment
with nitric oxide, the NO2 concentration should be < 0.5 ppm in the nitric oxide dose range < 20 ppm.
If at any time the NO2 concentration exceeds 1 ppm, the nitric oxide dose should immediately be
reduced. See section 4.2 for information on monitoring for NO2.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
In the presence of oxygen, nitric oxide is rapidly oxidised to derivatives which are toxic to the
bronchial epithelium and alveolo-capillary membrane. Nitrogen dioxide (NO2) is the main substance
formed, and may cause airway inflammation and damage. There are also animal data suggesting an
increased susceptibility to airway infections upon exposure to low levels of NO2. During treatment
with nitric oxide, the NO2 concentration should be < 0.5 ppm in the nitric oxide dose range < 20 ppm.
If at any time the NO2 concentration exceeds 1 ppm, the nitric oxide dose should immediately be
reduced. See section 4.2 for information on monitoring for NO2.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Due to a potential increase of haematological toxicity and bone marrow suppression, cladribine must
not be used concomitantly with other myelosuppressive medicinal products. An influence of cladribine
on the activity of other antineoplastic agents has not been observed in vitro (e.g. doxorubicin, vincristine,
cytarabine, cyclophosphamide) and in vivo. However, an in vitro study revealed cross-resistance
between cladribine and nitrogen mustard (chlormethine); for cytarabine, one author has described an
in vivo cross-reaction without loss of activity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-04-03T02:00:00Z · SHA-256 42ba8788ffbc14f662af334f85de7bff88a9741607012fc723ea0ee7baaee9b6 · Passage 0069b69facc95a08e23c3b2f659da5353a5d8d50062fae11d4956746b052392c · Zeichen 0–555 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.